CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
45.5%
49M of 107M shares
Institutional holders
137
23 new, 22 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
0 buys · 5 sales
Net sold $47.47K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,176,404 | 7.20% | 13G (passive) | Jun 30, 2026 |
| Rachel E. Haurwitz | 4,716,003 | 5.00% | 13D (active) | Apr 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRBU | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,815,843 | 7.29% | $13.76M | +5,672,758 | 0.00% |
| Pfizer Inc | 4,690,431 | 4.38% | $7.88M | – | 4.63% |
| Vanguard Capital Management LLC | 4,208,568 | 3.93% | $7.41M | +441,340 | 0.00% |
| Mackenzie Financial Corp | 3,650,796 | 3.41% | $6.43M | +2,708,010 | 0.01% |
| Renaissance Technologies LLC | 2,773,545 | 2.59% | $4.88M | +183,048 | 0.01% |
| Kynam Capital Management, LP | 2,503,302 | 2.34% | $4.41M | – | 0.24% |
| Geode Capital Management, LLC | 2,374,894 | 2.22% | $4.18M | +1,356,935 | 0.00% |
| Acadian Asset Management LLC | 1,774,474 | 1.66% | $3.12K | +849,435 | 0.00% |
| State Street Corp | 1,632,914 | 1.52% | $2.87M | +1,209,651 | 0.00% |
| Bank Of America Corp /De/ | 1,410,958 | 1.32% | $2.48M | +113,791 | 0.00% |
| Two Sigma Investments, LP | 1,046,279 | 0.98% | $1.84M | −713,655 | 0.00% |
| Dimensional Fund Advisors LP | 975,327 | 0.91% | $1.72M | +302,127 | 0.00% |
| Charles Schwab Investment Management Inc | 775,809 | 0.72% | $1.37M | +216,167 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 764,820 | 0.71% | $1.35K | +217,806 | 0.00% |
| FMR LLC | 727,115 | 0.68% | $1.28M | +3,156 | 0.00% |
| Northern Trust Corp | 712,965 | 0.67% | $1.25M | +495,230 | 0.00% |
| Maverick Capital Ltd | 652,542 | 0.61% | $1.15M | – | 0.01% |
| Vanguard Portfolio Management LLC | 613,801 | 0.57% | $1.08M | New | 0.00% |
| Vanguard Fiduciary Trust Co | 606,388 | 0.57% | $1.07M | +86,270 | 0.00% |
| Qube Research & Technologies Ltd | 545,755 | 0.51% | $960.53K | +369,058 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 137 | 49M | 45.5% | 23 / 47 | 23 / 22 | 17M | 6M |
| Q1 2026 | 137 | 38M | 35.3% | 28 / 27 | 41 / 13 | 10M | 5M |
| Q4 2025 | 124 | 37M | 34.7% | 25 / 29 | 35 / 14 | 6M | 6M |
| Q3 2025 | 117 | 37M | 34.7% | 16 / 21 | 47 / 28 | 4M | 8M |
| Q2 2025 | 129 | 41M | 38.6% | 34 / 28 | 42 / 36 | 6M | 15M |
| Q1 2025 | 131 | 50M | 46.9% | 19 / 36 | 41 / 19 | 5M | 12M |
| Q4 2024 | 133 | 58M | 54.4% | 27 / 48 | 27 / 22 | 13M | 8M |
| Q3 2024 | 129 | 53M | 49.3% | 19 / 43 | 32 / 28 | 13M | 7M |
| Q2 2024 | 140 | 54M | 50.0% | 27 / 40 | 44 / 36 | 12M | 26M |
| Q1 2024 | 151 | 68M | 63.5% | 27 / 44 | 46 / 20 | 8M | 10M |
| Q4 2023 | 144 | 71M | 66.0% | 30 / 55 | 31 / 12 | 10M | 10M |
| Q3 2023 | 126 | 71M | 66.0% | 28 / 58 | 19 / 21 | 33M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CRBU | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,013,973 | 2.81% | $5.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,292,562 | 2.14% | $4.03M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,113,215 | 1.04% | $1.96M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 997,353 | 0.93% | $1.46M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 881,080 | 0.82% | $1.55M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 628,598 | 0.59% | $1.11M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 450,523 | 0.42% | $1.06M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 425,172 | 0.40% | $1.00M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 308,420 | 0.29% | $542.82K | 0.04% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 255,338 | 0.24% | $372.79K | 0.00% | Jul 31, 2026 |
| Bruce Fund | 250,000 | 0.23% | $440.00K | 0.12% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 223,613 | 0.21% | $326.47K | 0.00% | Jul 31, 2026 |
| AXS Green Alpha ETF | 201,851 | 0.19% | $355.26K | 0.62% | Jun 30, 2026 |
| Master Small Cap Index Series | 171,661 | 0.16% | $302.12K | 0.01% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 170,883 | 0.16% | $249.49K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rachel E. Haurwitz | President and CEO, Director | 3,816,545 | 3.56% | Feb 20, 2026 |
| Timothy P. Kelly | Chief Technology Officer | 73,125 | 0.07% | Feb 27, 2026 |
| Barbara G. McClung | Chief Legal Officer | 481,564 | 0.45% | Feb 24, 2026 |
| Tina M. Albertson | Chief Medical Officer | 68,523 | 0.06% | Feb 24, 2026 |
| Ruhi Ahmad Khan | Chief Business Officer | 104,998 | 0.10% | Feb 24, 2026 |
| Sriram Ryali | Chief Financial Officer | 72,360 | 0.07% | Feb 20, 2026 |
| Steven Kanner | Chief Scientific Officer | 431,556 | 0.40% | Feb 21, 2025 |
| Ryan Fischesser | VP of Finance and Controller | 118,854 | 0.11% | Nov 22, 2024 |
| Natalie Sacks | Director | – | – | Feb 20, 2026 |
| Ran Zheng | Director | – | – | Feb 20, 2026 |
| Nancy Whiting | Director | – | – | Feb 20, 2026 |
| Dara Richardson-Heron | Director | – | – | Feb 20, 2026 |
| Scott Braunstein | Director | – | – | Feb 20, 2026 |
| David Lee Johnson | Director | – | – | Feb 20, 2026 |
| Andrew Guggenhime | Director | – | – | Feb 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Timothy P. Kelly Chief Technology Officer | Feb 25, 2026 | Sale | −6,228 | $1.93 | $12.02K | 73,125 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −6,938 | $1.96 | $13.60K | 104,998 |
| Tina M. Albertson Chief Medical Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,066 | $1.96 | $2.09K | 68,523 |
| Barbara G. McClung Chief Legal Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −6,938 | $1.96 | $13.60K | 481,564 |
| Timothy P. Kelly Chief Technology Officer | Feb 24, 2026 | Sale | −3,147 | $1.96 | $6.17K | 79,353 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 20, 2026 | Award | +45,000 | – | – | 111,936 |
| Tina M. Albertson Chief Medical Officer | Feb 20, 2026 | Award | +55,000 | – | – | 69,589 |
| Barbara G. McClung Chief Legal Officer | Feb 20, 2026 | Award | +45,000 | – | – | 488,502 |
| Timothy P. Kelly Chief Technology Officer | Feb 20, 2026 | Award | +45,000 | – | – | 82,500 |
| Sriram Ryali Chief Financial Officer | Feb 20, 2026 | Award | +55,000 | – | – | 72,360 |
| Rachel E. Haurwitz President and CEO, Director | Feb 20, 2026 | Award | +151,700 | – | – | 447,150 |
| Rachel E. Haurwitz President and CEO, Director | Mar 14, 2025 | Buy | +20,000 | $1.02 | $20.40K | 3,369,395 |
| Steven Kanner Chief Scientific Officer | Feb 21, 2025 | Sale(10b5-1 plan) | −3,564 | $1.35 | $4.81K | 431,556 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 21, 2025 | Sale(10b5-1 plan) | −3,564 | $1.35 | $4.81K | 66,936 |
| Barbara G. McClung Chief Legal Officer | Feb 21, 2025 | Sale(10b5-1 plan) | −3,564 | $1.35 | $4.81K | 443,502 |
| Steven Kanner Chief Scientific Officer | Feb 20, 2025 | Award | +37,500 | – | – | 435,120 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 20, 2025 | Award | +37,500 | – | – | 70,500 |
| Rachel E. Haurwitz President and CEO, Director | Feb 20, 2025 | Award | +136,750 | – | – | 295,450 |
| Timothy P. Kelly Chief Technology Officer | Feb 20, 2025 | Award | +37,500 | – | – | 37,500 |
| Tina M. Albertson Chief Medical Officer | Feb 20, 2025 | Award | +14,589 | – | – | 14,589 |
| Barbara G. McClung Chief Legal Officer | Feb 20, 2025 | Award | +37,500 | – | – | 447,066 |
| Sriram Ryali Chief Financial Officer | Jan 29, 2025 | Buy | +17,360 | $1.42 | $24.65K | 17,360 |
| Ryan Fischesser VP of Finance and Controller | Nov 20, 2024 | Award | +25,000 | – | – | 118,854 |
| Barbara G. McClung Chief Legal Officer | Feb 20, 2024 | Award | +33,000 | – | – | 409,566 |
| Steven Kanner Chief Scientific Officer | Feb 20, 2024 | Award | +33,000 | – | – | 387,037 |
| Jason O'Byrne Chief Financial Officer | Feb 20, 2024 | Award | +33,000 | – | – | 59,224 |
| Ruhi Ahmad Khan Chief Business Officer | Feb 20, 2024 | Award | +33,000 | – | – | 33,000 |
| Rachel E. Haurwitz President and CEO, Director | Feb 20, 2024 | Award | +118,700 | – | – | 158,700 |
| Steven Kanner Chief Scientific Officer | Feb 6, 2024 | Option exercise | +30,577 | $2.69 | $82.25K | 354,037 |
| Rachel E. Haurwitz President and CEO, Director | Jun 8, 2023 | Option exercise | +10,000 | $2.96 | $29.60K | 40,000 |
| Rachel E. Haurwitz President and CEO, Director | Mar 20, 2023 | Option exercise | +10,000 | $2.96 | $29.60K | 30,000 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Jan 19, 2023 | Sale | −5,627 | $6.31 | $35.51K | 59,373 |
| Steven Kanner Chief Scientific Officer | Dec 2, 2022 | Option exercise | +21,401 | $2.69 | $57.57K | 323,460 |
| Ryan Fischesser VP of Finance and Controller | Oct 6, 2022 | Sale | −10,000 | $10.80 | $108.00K | 110,366 |
| Ryan Fischesser VP of Finance and Controller | Oct 6, 2022 | Option exercise | +2,839 | $4.11 | $11.67K | 116,044 |
| Ryan Fischesser VP of Finance and Controller | Oct 6, 2022 | Option exercise | +2,839 | $2.69 | $7.64K | 113,205 |
| Barbara G. McClung Chief Legal Officer | Sep 15, 2022 | Option exercise | +27,518 | $2.69 | $74.02K | 376,566 |
| Barbara G. McClung Chief Legal Officer | Sep 15, 2022 | Option exercise | +77 | $2.69 | $207 | 349,048 |
| Steven Kanner Chief Scientific Officer | Aug 25, 2022 | Option exercise | +43,248 | $2.69 | $116.34K | 345,307 |
| Steven Kanner Chief Scientific Officer | Aug 25, 2022 | Sale(10b5-1 plan) | −43,248 | $11.22 | $485.24K | 302,059 |
| Ryan Fischesser VP of Finance and Controller | Aug 22, 2022 | Award | +4,848 | – | – | 120,366 |
| Steven Kanner Chief Scientific Officer | May 13, 2022 | Option exercise | +68,306 | $1.81 | $123.63K | 295,945 |
| Steven Kanner Chief Scientific Officer | May 13, 2022 | Option exercise | +6,114 | $2.69 | $16.45K | 302,059 |
| Rachel E. Haurwitz President and CEO, Director | May 9, 2022 | Option exercise | +10,000 | $2.96 | $29.60K | 20,000 |
| Ryan Fischesser VP of Finance and Controller | May 5, 2022 | Option exercise | +1,136 | $2.69 | $3.06K | 114,380 |
| Ryan Fischesser VP of Finance and Controller | May 5, 2022 | Option exercise | +1,138 | $4.11 | $4.68K | 115,518 |
| Ryan Fischesser VP of Finance and Controller | Mar 15, 2022 | Option exercise | +1,138 | $4.11 | $4.68K | 113,244 |
| Ryan Fischesser VP of Finance and Controller | Mar 15, 2022 | Option exercise | +1,136 | $2.69 | $3.06K | 112,106 |
| Steven Kanner Chief Scientific Officer | Mar 4, 2022 | Option exercise | +1,549 | $4.11 | $6.37K | 227,639 |
| Steven Kanner Chief Scientific Officer | Mar 4, 2022 | Option exercise | +9,171 | $2.69 | $24.67K | 226,090 |
| Jason O'Byrne Chief Financial Officer | Feb 8, 2022 | Option exercise | +24,336 | $4.11 | $100.02K | 24,336 |
| Rachel E. Haurwitz President and CEO, Director | Jan 26, 2022 | Option exercise | +10,000 | $2.96 | $29.60K | 10,000 |
| Rachel E. Haurwitz President and CEO, Director | Jan 26, 2022 | Option exercise | +10,000 | $2.96 | $29.60K | 3,359,395 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Jan 25, 2022 | Award | +60,000 | – | – | 65,000 |
| Ryan Fischesser VP of Finance and Controller | Jan 11, 2022 | Buy | +569 | $2.69 | $1.53K | 102,264 |
| Ryan Fischesser VP of Finance and Controller | Jan 11, 2022 | Buy | +6,818 | $4.11 | $28.02K | 109,082 |
| Ryan Fischesser VP of Finance and Controller | Dec 20, 2021 | Buy | +1,136 | $2.69 | $3.06K | 101,695 |
| Barbara G. McClung Chief Legal Officer | Dec 7, 2021 | Buy | +6,115 | $2.69 | $16.45K | 348,971 |
| Barbara G. McClung Chief Legal Officer | Dec 7, 2021 | Buy | +12 | $2.69 | $32 | 342,856 |
| Barbara G. McClung Chief Legal Officer | Oct 20, 2021 | Buy | +9,176 | $2.69 | $24.68K | 342,801 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kelly Timothy Officer | Feb 25, 2026 | 6,228 | $12.05K | Feb 25, 2026 | Restricted Stock |
| G. McClung Barbara Officer | Feb 25, 2026 | 6,938 | $13.60K | Feb 24, 2026 | Vesting of Restricted Stock Units |
| Ahmad Khan Ruhi Officer | Feb 25, 2026 | 6,938 | $13.60K | Feb 24, 2026 | Vesting of Restricted Stock Units |